Client CAMP4 Therapeutics Enters Research Collaboration With BioMarin Pharmaceutical to Develop RNA-Targeting Medicines for Genetic Diseases
October 04, 2024
October 04, 2024
BOSTON, Massachusetts, Oct. 4 -- Ropes and Gray, a law firm, issued the following news:
Ropes & Gray advised CAMP4 Therapeutics in a research collaboration with BioMarin Pharmaceutical aimed at advancing novel therapeutics that increase protein levels by targeting regulatory RNA sequences, which are key in controlling gene expression. The collaboration was announced on October 1.
Under the agreement, BioMarin will select two targets identified through CAMP4's RAP Pl . . .
Ropes & Gray advised CAMP4 Therapeutics in a research collaboration with BioMarin Pharmaceutical aimed at advancing novel therapeutics that increase protein levels by targeting regulatory RNA sequences, which are key in controlling gene expression. The collaboration was announced on October 1.
Under the agreement, BioMarin will select two targets identified through CAMP4's RAP Pl . . .